K-Beauty’s Intriguing ‘Return to Youth’ Treatment Sparks Global Interest
A startling anti-ageing trend is making waves in South Korea’s thriving beauty industry, sparking significant ethical and regulatory concerns globally. The treatment, known as Elravie Re2O (an acronym for “return to your 20s”), is a brainchild of Korean biotech firm L&C Bio. It involves the injection of a collagen-rich substance derived from the skin of deceased human donors. Despite its unsettling moniker, “corpse skin injection,” the demand for this treatment is skyrocketing.
The procedure employs a substance called human acellular dermal matrix (hADM). This is donated tissue that undergoes freezing, drying, pulverization, and genetic material removal, leaving behind structural proteins like collagen and elastin. Touted as a regenerative alternative to conventional fillers, it pledges to deliver firmer, smoother, and more elastic skin.
Initially designed for reconstructive medical procedures such as burn treatment and breast reconstruction, this material has found its way into the elective aesthetics market with minimal regulatory supervision. In response to this, Korea’s Ministry of Food and Drug Safety (MFDS) announced regulatory action in H1 2026, following a National Assembly forum that highlighted four key issues: the lack of clinical trials, absence of residue standards, technical contradictions in decellularization, and ethical concerns regarding donor intent.
Despite lacking approval from the U.S. FDA, select New York med spas are reportedly already offering this treatment. A survey revealed that 60.9% of 1,034 Korean adults are in favor of a ban or stringent restrictions on the cosmetic use of human tissue. However, L&C Bio has expressed its intention to officially introduce the product to the U.S. market by 2027.
Source: Yahoo News – “Would You Try an Anti-Aging Treatment Made From Donated Human Skin?”